R&G PharmaStudies Co., Ltd. (SHE:301333)

R&G PharmaStudies Revenue

R&G PharmaStudies had revenue of 218.09M CNY in the quarter ending March 31, 2026, with 26.18% growth. This brings the company's revenue in the last twelve months to 896.26M, up 21.20% year-over-year. In the year 2025, R&G PharmaStudies had annual revenue of 851.01M with 14.38% growth.

• Revenue (ttm): 896.26M
• Revenue Growth: +21.20%
• P/S Ratio: 6.67
• Revenue / Employee: 338.85K
• Employees: 2,645
• Market Cap: 5.98B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	851.01M	107.00M	14.38%
Dec 31, 2024	744.00M	22.63M	3.14%
Dec 31, 2023	721.37M	83.85M	13.15%
Jan 1, 2023	637.52M	29.09M	4.78%
Jan 1, 2022	608.43M	123.98M	25.59%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 9, 2026

Data Sources Report a data error